<DOC>
	<DOC>NCT02194153</DOC>
	<brief_summary>Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with MetalyseÂ® in a real life setting outside clinical trials.</brief_summary>
	<brief_title>Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Inclusion criteria: Male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. No patient younger than 18 years. Possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient Typical chest pain with a duration of more than 30 minutes Definite infarction signs in a 12leadECG with STelevation &gt; 0.1 millivolt (mV) in &gt; 2 leads or recent left bundle branch block with typical clinical signs Symptom onset &lt;= 6 hours Exclusion criteria: Patients older than 75 years (exception: patients appear much younger) Low body weight No persons under 18 contraindications according to summary of product characteristics (SPC) for Metalyse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>